Lung Cancer News, Features & Updates
- FDA Approves Jideytro for Advanced ROS1-Positive Lung Cancer
July 23, 2026 — The FDA has approved Jideytro (zidesamtinib) for adults with locally advanced or metastatic ROS1-positive non-small-cell lung cancer who received a prior ROS1 kinase inhibitor medicine.
- What EGFR-Positive Non-Small-Cell Lung Cancer Looks Like for Me
Here's what it's like to live with EGFR-positive non-small-cell lung cancer (NSCLC) — from treatment ups and downs to finding community.
- Advanced Lung Cancer: First- vs. Second-Line Therapy
Learn how first- and second-line treatment options for extensive-stage small-cell lung cancer differ, including drugs, side effects, and new therapies.
- How to Handle the First Few Days After Learning Your SCLC Has Spread
Once you get through the shock of your diagnosis, the right support can help you process your emotions and move forward.
- Small-Cell Lung Cancer (SCLC): When ‘Staying Positive’ Doesn’t Help
You don’t have to be upbeat all the time with SCLC. It’s normal to feel a range of emotions. Four advocates share how they came to terms with their diagnosis and found peace.
- When to Continue or Stop Treatment for Advanced Small-Cell Lung Cancer: Expert Guidance
How do you decide when to stop treating your advanced small-cell lung cancer? An oncologist answers questions to help guide your decision.
- I'm a Respiratory Therapist. Here Are the Breathing Exercises I Teach My Patients With Lung Cancer
Breathing exercises can help you cope with symptoms of lung cancer such as shortness of breath. Here, a respiratory therapist provides his top choices.
- How Palliative Care Helps With SCLC — And Why It’s Not Just for End of Life
Palliative care, or supportive care, can help you manage SCLC symptoms and treatment side effects, create care goals, and improve quality of life.
- Living Alone With NSCLC? Here Is How to Stay Safe and in Control
How do you stay safe and in control of your life with non-small cell lung cancer? Find out some survival tips.
- Resistance to EGFR Therapy in Lung Cancer: Why It Happens and What to Do Next?
Learn what treatment resistance means when you have EGFR-mutated lung cancer, and what you can expect and do if it happens.
- An Expert Explains Why Targeted Therapy Works
Learn right from an expert why targeted therapy is the best way to treat EGFR-mutated non-small cell lung cancer (NSCLC).
- From Facebook to Face-to-Face: How Cancer Support Works Now
Lung cancer support looks different for everyone. From support groups to volunteering to conferences, here’s how to find the right village for you.
- I’m an Oncologist. Here’s How I Estimate Lung Cancer Prognosis and Why It’s Not Set in Stone
Learn how oncologists may come up with their prognosis for your lung cancer using facts about you and your tumor.
- How Therapy Can Help When You Have Lung Cancer
Talk therapy can help you navigate the challenges of lung cancer treatment. Here’s why it can help, and what to look for in a mental health provider
- Letting Go of Self-Blame in Lung Cancer
Lung cancer carries stigma and self-blame. But strategies like CBT and support groups encourage self-compassion. Here are tips for self care.
- Life After Lung Removal: What to Expect Post-Lobectomy or Pneumonectomy
Four people who have had lung removal surgery and one thoracic surgeon talk you through what to expect.
- Why Lung Cancer Feels So Lonely (and What Helped Me Find Hope)
Lung cancer can feel isolating. Learn about stigma, loneliness, and practical ways to stay connected during treatment.
- Lung Cancer and Your Job: Rights, Disability Types, and Accommodations
What to know about working after lung cancer, including workplace rights, accommodations, medical leave, and how to talk to your employer
- I’m an Oncologist. Here’s What I Tell Patients Newly Diagnosed With Lung Cancer
An oncologist shares what he tells people newly diagnosed with lung cancer, including treatment steps and what to do first.
- Hernexeos: FDA Approves First-Line Use for Certain Advanced Non-Small-Cell Lung Cancers With HER2 Mutations
February 27, 2026 — The FDA has approved Hernexeos (zongertinib) as a first-choice treatment for adults with non-small-cell lung cancer whose tumors have specific genetic changes, as confirmed by an FDA-authorized test.
- Lung Nodules: Understanding the Results
Are lung nodules always cancer? Learn more about what lung nodules mean for your health.
- Rybrevant Faspro: FDA Approves Once-Monthly Dosing in Combination With Lazcluze for EGFR-Mutated Lung Cancer
February 20, 2026 — The FDA has approved a new monthly dosing option for Rybrevant Faspro to be used with lazertinib (Lazcluze) as a first‑line treatment for people with advanced non‑small-cell lung cancer who have certain mutations in the epidermal growth factor receptor (EGFR) gene.
- FDA Approves Rybrevant Faspro: A Time-Saving Under-the-Skin Injection for Use in Combination With Lazcluze for EGFR-Mutated Lung Cancer
February 18, 2026 — The FDA has approved the use of Rybrevant Faspro, combined with another medicine, as a first-line treatment for non-small-cell lung cancer (NSCLC) that has certain mutations in the EGFR (epidermal growth factor receptor) gene.
- Expert Q&A: A Doctor's Experience With SCLC
Get insight from an oncologist about her experiences in diagnosing, treating, helping, motivating, and consoling patients as they live with small-cell lung cancer.
- Living With Small-Cell Lung Cancer
Learn what life is like living with small-cell lung cancer. A patient shares experience with getting diagnosed and going through treatments, along with triumphs and challenges as they live with SCLC.
- Getting Diagnosed With SCLC: My Story
Get insight from a patient about her experiences with getting diagnosed, getting treated, working through issues, and staying motivated and hopeful as she lives with small-cell lung cancer.
- Recent Advances in Small-Cell Lung Cancer
Learn about what's on the horizon for small-cell lung cancer, including treatments and diagnostic tests.
- FDA Approves Rybrevant Faspro: An Under-the-Skin Injection for Use in Combination With Lazcluze for EGFR-Mutated Lung Cancer
December 18, 2025 — The FDA has approved Rybrevant Faspro in combination with another medicine called lazertinib (Lazcluze) as a first-line treatment for a type of lung cancer called non-small-cell lung cancer (NSCLC) that has certain genetic changes (mutations) in the EGFR (epidermal growth factor receptor) gene.
- Hope on the Horizon: Ongoing Research in EGFR Exon 20 Insertion Mutation
Recent FDA approvals and ongoing clinical trials show promise for the treatment landscape of EGFR exon 20 insertion-mutated lung cancer.
- My Diagnosis Story: EGFR Exon 20 Insertion Mutation
One woman living with EGFR exon 20 insertion mutated cancer shares her diagnosis story and shares advice for others facing a similar journey.
- Expert Q&A: A Doctor’s Experience With EGFR Exon 20 Insertion Mutation
A doctor gives her insights on NSCLC with EGFR exon 20 insertion mutation, explaining what it is, who gets it, how it’s treated, and more.
- Hyrnuo: New Oral Treatment for Advanced HER2-Mutant Lung Cancer
November 24, 2025 — Hyrnuo (sevabertinib) is a new oral kinase inhibitor medicine for adults with advanced nonsquamous non-small-cell lung cancer (NSCLC) carrying a specific genetic change and whose cancer has either advanced locally or has spread to other parts of the body.
- Imdelltra Receives Full FDA Approval as First-In-Class Immunotherapy for Advanced Small-Cell Lung Cancer
November 21, 2025 — Imdelltra (tarlatamab-dlle) is a first-of-its kind targeted cancer medicine called a bispecific T-cell engager approved for treating adults with extensive-stage small-cell lung cancer (ES-SCLC) that has gotten worse on or after chemotherapy with platinum-based cancer drugs.
- My Diagnosis Story: HER2-Mutated Non-Small-Cell Lung Cancer
Samantha Murrell shares the challenges and frustrations of getting her HER2-mutated NSCLC diagnosis and what she’s learned from the experience.
- Expert Q&A: A Clinician’s Experience With HER2-Mutated Non-Small-Cell Lung Cancer
Thoracic oncologist Tarik Hadid, MD, MPH, offers his clinical expertise on HER2-mutated non-small-cell lung cancer.
- Recent Advances in HER2-Mutated Non-Small-Cell Lung Cancer
Doctors have more genetic insight and treatment options for HER2-mutated non-small-cell lung cancer than ever before.
- FDA Approves Combined Use of Zepzelca and Atezolizumab as First-Line Maintenance Treatment for Advanced Small-Cell Lung Cancer
October 3, 2025 — The FDA has approved the combined use of two medicines – Zepzelca and atezolizumab – as first-line maintenance therapy for adults with extensive-stage small-cell lung cancer whose cancer has not worsened after immunotherapy and chemotherapy.
- Hernexeos (Zongertinib) Approved as the First Oral Targeted Treatment for HER2-Mutant Advanced Lung Cancer
August 11, 2025 — Hernexeos (zongertinib) is a new pill for adults with a type of advanced lung cancer called non-small-cell lung cancer (NSCLC) that has a HER2 gene mutation that causes the cancer to grow and spread faster, especially to the brain.
- FDA OKs First-of-Its-Kind Lung Cancer Pill
July 7, 2025 — The FDA has granted quick approval to sunvozertinib (sold as Zegfrovy) a first-of-its-kind pill for a type of lung cancer known as non-small-cell lung cancer (NSCLC).
- FDA OKs New Next-Gen Pill for Rare Lung Cancer
June 12, 2025 — The FDA has approved an oral pill called taletrectinib (Ibtrozi) to treat people who have a rare type of non-small-cell lung cancer (NSCLC) that is linked to a faulty ROS1 gene and has spread or worsened.
- FDA OKs New Treatment for Hard-to-Treat Lung Cancer
May 16, 2025 — The FDA has granted fast-track approval to the drug telisotuzumab vedotin (sold as Emrelis) as a first-of-its-kind treatment for certain people who have non-squamous non-small-cell lung cancer.
- FDA Approves New Drug for Advanced Lung Cancer
December 19, 2024 — The FDA has approved a new drug called ensartinib for adults with a type of lung cancer called ALK-positive non-small-cell lung cancer (NSCLC).
- mRNA Lung Cancer Vaccine Could Be Revolutionary Treatment
December 17, 2024 — A new vaccine to treat non-small-cell lung cancer is undergoing phase I trials and offering a potential breakthrough in immunotherapy.
- FDA Approves Drug for Aggressive Small-Cell Lung Cancer
December 9, 2024 — The FDA has approved the drug durvalumab for adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease hasn’t gotten worse after getting platinum-based chemo and radiation at the same time.
- FDA Approves New Treatment for Non-Small-Cell Lung Cancer
August 21, 2024 — Clinical trials showed patients lived longer without disease progression, compared to the standard treatment currently used.
- Lung Cancer Drug’s 'Off-the-Charts’ Results Give Patients Hope
June 6, 2024 — Researchers believe the drug could make certain kinds of lung cancers a chronic disease like diabetes, and not necessarily a death sentence.
- Trend Rolls On: Women at Higher Lung Cancer Risk
October 13, 2023 — Researchers are calling for intensified smoking cessation efforts and lung screenings among young and middle-aged women after a new analysis showed they are increasingly more likely than men to be diagnosed with lung cancer. The trend has been under way in recent years.
- Focus on the Mental Impact of Inoperable Lung Cancer
Physical impacts of inoperable lung cancer are widely discussed, but the mental impact is not. Arif Kamal, MD, shares why it’s key and how to find help.
- What I’ve Learned From My Patients About The Challenges of Inoperable Lung Cancer
A pulmonologist describes how, though lung cancer may remain inoperable, targeted therapies and early screening have changed the game.
